logo
WATCH: Rare ‘Black Demon' fish spotted alive for first time

WATCH: Rare ‘Black Demon' fish spotted alive for first time

Yahoo10-02-2025
(WJW) – A deep-sea anglerfish, known as the Black Demon, had a rare spotting off the coast of Tenerife in the Canary Islands.
Condrik Tenerife, which specializes in shark and ray research and conservation in the Canary Islands, described the sighting as a 'surprising find.'
Local school unexpectedly delays due to 'bus de-icing'
Marine Wildlife Photographer David Jara Boguñá posted a video of the sighting saying, 'This could be the first recorded sighting in the world of a black demon or adult abyssal (Melanocetus johnsonii) alive, in broad daylight and on the surface!!'
Condrik Tenerife said the fish was a humpback anglerfish, a type of black seadevil.
The scary-looking fish is usually found in water depths of 1,500 meters, where little to no sunlight reaches and where it uses its bioluminescent light to attract its prey.
'To date, records have mostly consisted of larvae, dead adults, or specimens spotted by submarines during deep-sea scientific expeditions,' Condrik Tenerife said.
Did you spot them? 2025 Super Bowl champs with ties to NE Ohio
Condrik Tenerife also described the animal as, 'A legendary fish that few people will have had the privilege of observing alive.'
'Apparently, the existing records to date correspond to larvae, dead adult specimens or those recorded with submarines,' Boguñá said on Instagram. 'The motive for its presence in such shallow waters is uncertain. Maybe due to illness, an upstream, fleeing a predator, etc.'
The encounter was described as a 'surprising find' that will be remembered forever.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New Mexico Museum of Natural History & Science to host community celebration before temporary closure
New Mexico Museum of Natural History & Science to host community celebration before temporary closure

Yahoo

time2 days ago

  • Yahoo

New Mexico Museum of Natural History & Science to host community celebration before temporary closure

ALBUQUERQUE, N.M. (KRQE) – The New Mexico Museum of Natural History & Science will be hosting a community 'closing celebration' on Aug. 3, one day before the museum is set to temporarily shut its doors for its first major renovation in decades. Officials said they plan to make a new entrance including rebuilding the lobby, add a new ticket booth, expand the gift shop, refresh permanent exhibition halls, replace the skylights in the atrium and Cretaceous Hall and update the main sewer line. Village of Ruidoso says its ready to welcome visitors back after devastating floods The 'Closing Celebration will take place at the museum from 11 a.m. to 4 p.m. and will feature all-ages activities including face-painting, balloon animals, and more. Vistiors will also be able to catch a free show in the Verus Research DynaTheater or the Planetarium, and get their picture taken with the roaring Bisti Beast, Bonita, on the museum's 2nd floor. The museum expects to open back up in March 2026, and plans to have a 40th anniversary celebration for the museum, which opened in 1986. To learn more about the temporary closure of the museum on Aug. 4, click here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword

Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device
Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device

Business Wire

time2 days ago

  • Business Wire

Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Venova Technologies, Inc., a women-led startup developing a novel long-acting, hormone-free and copper-free female birth control device, has been awarded a $2.23M Small Business Innovation Research (SBIR) Phase II Grant from the National Institutes of Health (NIH). The SBIR program is a highly competitive, awards-based program designed to stimulate technological innovations developed by U.S. small businesses on a path to commercialization. This Phase II award accelerates the preclinical development of Venova's innovative cervical barrier device toward first-in-human clinical studies and brings the company's total funding to over $5M. According to a UCLA survey, 73% of women want a birth control method that is very effective and has limited side effects, but this does not currently exist. A 2023 study found that half of women will stop or switch their birth control method because of unwanted or adverse side effects. 'This award is a pivotal milestone that brings us one step closer to offering a new birth control option for women that is designed to be side-effect-free and addresses concerns of pain from IUD insertion,' said Emily Man, Co-Founder & CEO of Venova. 'Validation from the scientific community highlights the growing momentum and critical need for innovation in women's health.' 'It's more important than ever to provide a wide range of choices for contraception that can meet the needs of more patients,' said Dr. Katharine White, Chair of Obstetrics and Gynecology at Boston University Chobanian & Avedisian School of Medicine and Chief of Obstetrics and Gynecology for the Boston Medical Center Health System. Dr. White is also the Chief Medical Advisor at Venova. 'Offering more affordable options that address a variety of preferences will enable more women to achieve the family size that they truly desire.' About Venova Technologies Venova Technologies, Inc., is a women-led startup dedicated to empowering women to take full control over their reproductive health. The company is developing a novel long-acting female contraceptive barrier device. Headquartered in Cambridge, Mass., at The Engine built by MIT, Venova participates in this premier ecosystem for high-potential, Tough Tech startups. For more information, visit Follow Venova on LinkedIn at

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Yahoo

time2 days ago

  • Yahoo

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizationsFRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community. 'Derek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma,' said Frank Stokes, chief financial officer of Castle Biosciences. 'Over nearly two decades, his leadership approach has exemplified how great vision and values can drive meaningful progress – building a company culture where patient needs remain at the center of strategic decisions and where personalized disease insights can translate into better care for those who need it most.' 'I am truly honored to receive this recognition from the Houston Business Journal,' said Maetzold. "This award validates our core belief that lasting impact comes from doing right by our team and never losing sight of the patients who depend on our work.' The award recipients will be honored at a special event held by the Houston Business Journal in August. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc. Photos accompanying this announcement are available at: in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store